GLP1R and neurodegenerative disease: In our current study, we hope to provide preclinical evidence that incretin-based multi-agonists may have enhanced success in mitigating neurodegenerative processes as compared to single GLP-1R agonists, and thus are promising candidates for repurposing in future neurodegenerative disease clinical trials.